Kodiak Sciences Inc. $KOD Holdings Raised by UBS Group AG

UBS Group AG lifted its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 197.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 168,562 shares of the company’s stock after acquiring an additional 111,853 shares during the period. UBS Group AG’s holdings in Kodiak Sciences were worth $4,713,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Boone Capital Management LLC bought a new stake in shares of Kodiak Sciences during the third quarter valued at about $11,719,000. TD Asset Management Inc acquired a new position in Kodiak Sciences during the third quarter worth about $992,000. Campbell & CO Investment Adviser LLC acquired a new position in Kodiak Sciences during the third quarter worth about $488,000. Vanguard Group Inc. grew its holdings in Kodiak Sciences by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 2,313,395 shares of the company’s stock worth $64,683,000 after acquiring an additional 363,103 shares during the period. Finally, Bridgeway Capital Management LLC grew its holdings in Kodiak Sciences by 8.2% during the second quarter. Bridgeway Capital Management LLC now owns 101,900 shares of the company’s stock worth $380,000 after acquiring an additional 7,700 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Wall Street Zen raised Kodiak Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $14.00 to $61.00 in a research report on Monday, May 11th. HC Wainwright restated a “buy” rating and set a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a research report on Friday, March 27th. Finally, UBS Group raised their price objective on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.14.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $37.41 on Friday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -8.97 and a beta of 2.32. Kodiak Sciences Inc. has a 52-week low of $3.26 and a 52-week high of $47.84. The stock has a 50-day simple moving average of $37.26 and a 200-day simple moving average of $28.96.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.01). As a group, equities research analysts predict that Kodiak Sciences Inc. will post -3.89 earnings per share for the current year.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.